Will Junshi Bio's Loss-Making Headaches Ease With Landmark U.S. Drug Approval?
Key Takeaways:
Junshi Bio will receive milestone payments and 20% of sales of its PD-1 drug Toripalimab in the U.S., following the drug’s recent approval by the FDA
The drug maker’s revenue fell 19% year-on-year in the first nine months of 2023, as its net loss narrowed to 1.41 billion yuan
By Molly Wen